



Lyve-1x  $\beta$ -gal :  $\beta$ -gal genetically expressed in LEC and hematopoietically-derived CD45<sup>+</sup> cells




Prox1x  $\beta$ -gal :  $\beta$ -gal genetically expressed in LEC

**Supplementary Figure 1: Graphical representation of  $\beta$ -gal<sup>+</sup> mouse models used.** Lyve-1-cre x Rosa26<sup>stop-LacZ</sup> (Lyve-1x  $\beta$ -gal) mice genetically express  $\beta$ -gal in LECs and some CD45<sup>+</sup> cells, whereas Prox1-creER<sup>T2</sup> x Rosa26<sup>stop-LacZ</sup> (Prox1x  $\beta$ -gal) mice genetically express  $\beta$ -gal in LECs but not CD45<sup>+</sup> cells.




**Supplementary Figure 2:  $\beta$ -gal specific CD8 T-cells delete via the PD-1/PD-L1 and LAG-3/MHC-II pathways after recognizing antigen expressed by LECs.**

(A-C) CTV-labeled Thy1.1<sup>+</sup> Bg1 cells were adoptively transferred along with CTV-labeled Thy1.1<sup>neg</sup> cells as an injection control. Skin-draining LN were analyzed for Bg1 proliferation and the indicated markers 3 days later. (D) Representative data from Figure 3D is shown. Plots are gated on total CD8<sup>+</sup> T-cells in (A, D), CD8<sup>+</sup>Thy1.1<sup>+</sup> Bg1 cells in (B), and on proliferating CD8<sup>+</sup>Thy1.1<sup>+</sup> Bg1 cells in (C). Numbers in (B) represent the percent of dividing (left number) or undivided (right number) Bg1 cells that express the indicated marker. Data representative of 2-3 experiments with 1-3 mice each (A-C) or 2 experiments with 1-2 mice each (D).




### Supplementary Figure 3: LECs do not present HA on MHC-II molecules

(A) Representative data from co-culture in Figure 5A is shown. (B) CTV-labeled Thy1.1<sup>+</sup> TS1 cells were transferred into the indicated recipients, and CD69 was analyzed 16 hours after transfer. Plot is gated on Thy1.1<sup>+</sup> CD4<sup>+</sup> cells. Data representative of 2 experiments with 1-2 mice each. (C) CTV-labeled Thy1.1<sup>+</sup> TS1 cells were transferred into the indicated recipients, along with CTV-labeled Thy1.1<sup>neg</sup> cells as an injection control. Proliferation was measured 3 or 7 days later. Plot is gated on CD4<sup>+</sup> cells. Data representative of 1-2 mice from 1 experiment.



**Supplementary Figure 4: BALB/c LECs express I-E $\alpha$ , but B6 LECs do not.** LECs, FRCs, BECs, macrophages, and DCs from Balb/c or B6 mice were sorted by flow cytometry as in Figure 1, and cultured 3T3 cells were harvested. mRNA was purified and qPCR was performed for *H2-Ea-ps*. Data from 2 independent experiments with LN pooled from 4-5 mice. Nd, not detected.



### Supplementary Figure 5: LECs express cathepsin L but not H-2O

(A) The percent of endosomes containing cathepsin L in each LEC was calculated using ImageJ, and histograms were computed using Prism. A representative immunofluorescent image is shown in Figure 6B. (B) LN-LECs or D-LECs were preincubated with the cathepsin L inhibitor 1-naphthalenesulfonyl-IW-CHO or DMSO vehicle control for 20 minutes at 37°C, followed by a 20 minute incubation with the cathepsin L substrate (CBZ-Phe-Arg)<sub>2</sub>-rhodamine 110 at 37°C, and rhodamine 110 fluorescence was measured by flow cytometry. (C) LECs and B cells were stained for MHC-II and H-2O intracellularly. (A) shows data from 17 cells from 2

separate experiments. Data in B is from 2 experiments with LN pooled from 1-2 mice, and (C) is representative of 2 independent experiments.

Mouse strain	Mouse background	Constitutive or induced cre	Antigen	Antigen genetically expressed in:	Notes
Lyve-1x $\beta$ -gal	B6	Constitutive	$\beta$ -gal	LECs, CD45 <sup>+</sup> cells	
MHC-I <sup>-/-</sup> →Lyve-1x $\beta$ -gal bone marrow chimeras	B6	Constitutive	$\beta$ -gal	LECs	No genetic antigen or MHC-I expression in CD45 <sup>+</sup> cells
MHC-II <sup>-/-</sup> →Lyve-1x $\beta$ -gal bone marrow chimeras	B6	Constitutive	$\beta$ -gal	LECs	No genetic antigen or MHC-II expression in CD45 <sup>+</sup> cells
Prox1x $\beta$ -gal	B6	Tamoxifen induced	$\beta$ -gal	LECs	
MHC-II <sup>-/-</sup> →Prox1x $\beta$ -gal bone marrow chimeras	B6	Tamoxifen induced	$\beta$ -gal	LECs	Bone marrow-derived CD45 <sup>+</sup> cells are MHC-II <sup>-/-</sup>
Prox1xHA	(B6 x Balb/c) F1	Tamoxifen induced	HA	LECs	
MHC-II <sup>-/-</sup> →Prox1xHA bone marrow chimeras	(B6 x Balb/c) F1	Tamoxifen induced	HA	LECs	Bone marrow-derived CD45 <sup>+</sup> cells are MHC-II <sup>-/-</sup>

**Supplementary Table 1: Antigen-expressing mouse strains used**

Mouse strain	Mouse background	Antigen recognized	CD4 or CD8	Restriction element
Bg1	B6	$\beta$ -gal	CD8	H2-K <sup>b</sup>
Bg2	B6		CD4	I-A <sup>b</sup>
Clone 4	(B6 x Balb/c) F1	HA	CD8	H-2K <sup>d</sup>
TS1	(B6 x Balb/c) F1		CD4	I-E <sup>d</sup>

**Supplementary Table 2: TCR-transgenic mouse strains used**